OBJECTIVE: Interleukin-1 (IL-1) is known to be critically involved in ovarian carcinogenesis. We investigated a panel of polymorphisms of the IL-1 and the IL-1 receptor antagonist (IL-1 RA) genes in patients with ovarian cancer. METHODS: One hundred thirty-four patients with surgically staged ovarian cancer, 27 patients with borderline ovarian cancer, and 134 healthy controls were genotyped for three polymorphisms of the IL-1 gene (-889 C/T polymorphism of the IL-1alpha gene [IL1A], -511 C/T polymorphism of the IL-1beta promoter [IL1B promoter], a polymorphism of IL-1beta exon 5 [IL1B exon 5]), and an 86-base pair repeat in intron 2 of the IL-1 RA gene [IL1RN]) using polymerase chain reaction and pyrosequencing. RESULTS: Allelic frequencies did not differ between patients with ovarian cancer and controls. In the ovarian cancer group, polymorphism did not correlate with any of the investigated clinicopathologic variables, including tumor stage, lymph node, and histologic grade. In univariate and multivariate models, there was no correlation between any polymorphism and patients' overall and disease-free survival. CONCLUSION: We investigated interleukin polymorphisms in ovarian cancer but did not find any association between common polymorphisms of IL1A, IL1B, and IL1RN and the occurrence of ovarian cancer. Allelic variation within the IL-1 gene clusters does not seem to play a role in ovarian carcinogenesis and does not appear to be a useful tool for possible screening and risk evaluation.
OBJECTIVE:Interleukin-1 (IL-1) is known to be critically involved in ovarian carcinogenesis. We investigated a panel of polymorphisms of the IL-1 and the IL-1 receptor antagonist (IL-1 RA) genes in patients with ovarian cancer. METHODS: One hundred thirty-four patients with surgically staged ovarian cancer, 27 patients with borderline ovarian cancer, and 134 healthy controls were genotyped for three polymorphisms of the IL-1 gene (-889 C/T polymorphism of the IL-1alpha gene [IL1A], -511 C/T polymorphism of the IL-1beta promoter [IL1B promoter], a polymorphism of IL-1beta exon 5 [IL1B exon 5]), and an 86-base pair repeat in intron 2 of the IL-1 RA gene [IL1RN]) using polymerase chain reaction and pyrosequencing. RESULTS: Allelic frequencies did not differ between patients with ovarian cancer and controls. In the ovarian cancer group, polymorphism did not correlate with any of the investigated clinicopathologic variables, including tumor stage, lymph node, and histologic grade. In univariate and multivariate models, there was no correlation between any polymorphism and patients' overall and disease-free survival. CONCLUSION: We investigated interleukin polymorphisms in ovarian cancer but did not find any association between common polymorphisms of IL1A, IL1B, and IL1RN and the occurrence of ovarian cancer. Allelic variation within the IL-1 gene clusters does not seem to play a role in ovarian carcinogenesis and does not appear to be a useful tool for possible screening and risk evaluation.
Authors: Kristin L White; Joellen M Schildkraut; Rachel T Palmieri; Edwin S Iversen; Andrew Berchuck; Robert A Vierkant; David N Rider; Bridget Charbonneau; Mine S Cicek; Rebecca Sutphen; Michael J Birrer; Paul P D Pharoah; Honglin Song; Jonathan Tyrer; Simon A Gayther; Susan J Ramus; Nicolas Wentzensen; Hannah P Yang; Montserrat Garcia-Closas; Catherine M Phelan; Julie M Cunningham; Brooke L Fridley; Thomas A Sellers; Ellen L Goode Journal: Cancer Res Date: 2012-01-26 Impact factor: 12.701
Authors: Sebastian Niedźwiecki; Tomasz Stepień; Krzysztof Kuzdak; Henryk Stepień; Roman Krupiński; Daniel Seehofer; Nada Rayes; Frank Ulrich Journal: Langenbecks Arch Surg Date: 2007-12-07 Impact factor: 3.445
Authors: Pablo Sáenz-López; Rafael Carretero; José Manuel Cózar; José Maria Romero; Julia Canton; José Ramón Vilchez; Miguel Tallada; Federico Garrido; Francisco Ruiz-Cabello Journal: BMC Cancer Date: 2008-12-19 Impact factor: 4.430
Authors: S P Balasubramanian; I A F Azmy; S E Higham; A G Wilson; S S Cross; A Cox; N J Brown; M W Reed Journal: BMC Cancer Date: 2006-07-14 Impact factor: 4.430